GLP-1 peptide research overview

A literature-cited research overview of the incretin receptor agonist peptide class — the endogenous GLP-1 system, the structural modifications that turned native GLP-1 into long-acting analogs like Semaglutide, the rationale for dual and tri-agonist designs like Tirzepatide and Retatrutide, and the core published literature behind each mechanism.

The endogenous GLP-1 system

Glucagon-like peptide-1 is a 30- or 31-amino-acid peptide cleaved from the preproglucagon gene product in enteroendocrine L-cells of the distal small intestine and colon. Secretion is triggered by luminal nutrients, particularly glucose and lipids. GLP-1 binds the GLP-1 receptor, a class B1 G-protein coupled receptor expressed on pancreatic β-cells, α-cells, gastric smooth muscle, central nervous system neurons in the hypothalamus and brainstem, and several other tissues. At the β-cell, GLP-1R activation potentiates glucose-stimulated insulin secretion via cAMP-dependent pathways.

Native GLP-1 is not a practical therapeutic peptide. It has a plasma half-life of approximately 1–2 minutes because the N-terminal His-Ala sequence is a substrate for dipeptidyl peptidase-4 (DPP-4), which cleaves the peptide to an inactive form, and because the short peptide is rapidly cleared renally. Drucker's 2018 review in Cell Metabolism (PMID: 29514064) summarizes the native GLP-1 biology and the pharmacological constraints that drove the analog design programs.

Semaglutide: structural engineering for a one-week half-life

Semaglutide is a synthetic analog of human GLP-1 with three engineered modifications that together extend the plasma half-life from minutes to approximately one week. At position 8, Ala is replaced with Aib (alpha-aminoisobutyric acid). The Aib substitution is not a substrate for DPP-4, eliminating the primary enzymatic clearance pathway. At position 34, Lys is replaced with Arg, removing an off-target acylation site so that a fatty-acid conjugation can be directed specifically to Lys26. At Lys26, a C18 fatty diacid is attached through a γGlu-2xOEG (two 8-amino-3,6-dioxaoctanoic acid units) spacer.

The C18 fatty-diacid side chain binds reversibly to serum albumin. Albumin-bound peptide is protected from renal filtration and serves as a circulating reservoir, releasing free peptide over time. The net effect is a peptide with a plasma half-life of approximately 165–184 hours in human subjects, supporting weekly administration schedules. Lau et al. describe the design and SAR in J Med Chem 2015 (PMID: 26308095). Semaglutide's FDA-approved pharmaceutical forms (subcutaneous Ozempic and Wegovy, oral Rybelsus) are manufactured under GMP for clinical use; research-grade Semaglutide is a separate category distributed for in-vitro laboratory research.

Tirzepatide: dual GLP-1/GIP agonism

Tirzepatide extends the incretin-agonist concept to a second receptor. Glucose-dependent insulinotropic polypeptide (GIP) is the other major incretin, secreted from K-cells in the upper small intestine, signaling through GIPR, and responsible for a large fraction of the normal incretin effect in healthy physiology. Native GLP-1 binds only GLP-1R; Semaglutide binds only GLP-1R. Tirzepatide is engineered as a single peptide that binds both GLP-1R and GIPR with reasonable potency at each.

Structurally, Tirzepatide is a 39-amino-acid peptide based on the native GIP backbone, modified at positions that recruit GLP-1R binding and engineered with a C20 fatty diacid side chain for albumin-mediated half-life extension similar to Semaglutide's approach. The rationale for dual agonism is that GIP and GLP-1 drive complementary metabolic and satiety pathways, and that simultaneously engaging both receptors produces effects not achievable with GLP-1 agonism alone. Coskun et al. describe the molecular pharmacology of Tirzepatide in Mol Metab 2018 (PMID: 30473097). Tirzepatide's FDA-approved pharmaceutical forms (Mounjaro and Zepbound) are again GMP clinical product distinct from research-grade material.

Retatrutide: triple agonism and glucagon-receptor involvement

Retatrutide (Eli Lilly compound LY3437943) extends the multi-agonist approach further by adding the glucagon receptor (GCGR) as a third target. The glucagon receptor is canonically associated with hepatic glucose output, but it also contributes to energy expenditure and hepatic lipid metabolism. The hypothesis behind including GCGR agonism in a multi-receptor design is that it adds an energy-expenditure component to the incretin effects of GLP-1 and GIP engagement.

Retatrutide is a 39-amino-acid peptide engineered for balanced activity at GLP-1R, GIPR, and GCGR, with a fatty-diacid lipidation strategy similar to the other compounds in the class. Jastreboff et al. reported Phase 2 obesity data in N Engl J Med 2023 (PMID: 37366315) showing dose-dependent effects at 48 weeks across the 1–12 mg dose range. Retatrutide is investigational and has not been FDA approved; Phase 3 trial programs are ongoing at the time of writing.

Receptor signaling and biased agonism

An active area of incretin-class research is receptor signaling bias — the observation that different GLP-1R agonists can preferentially activate different downstream pathways (Gs/cAMP versus β-arrestin recruitment, for instance) at the same receptor. Biased agonism has implications for the tissue-selective effects of different compounds and is reviewed in Müller, Finan, Bloom, D'Alessio, Drucker, Flatt et al. (Mol Metab 2019, PMID: 31767182). For the multi-agonist compounds, additional layers of pharmacology emerge from the relative potency balance across the two or three receptors engaged by a single peptide. These structure-activity and signaling questions are the research substrate the class continues to produce literature on.

Research framing

Aurex distributes Semaglutide, Tirzepatide, and Retatrutide as lyophilized research-grade analytical material, batch-verified at Janoshik Analytical, for in-vitro laboratory research by qualified researchers. The peptides themselves are the same molecular species as the clinical pharmaceutical products, but the regulatory status, packaging, labeling, sterility, and authorized use are different. Research-grade material is not a clinical product. No dosing protocols for human use are provided on this page or anywhere else on the Aurex site; the available product pages and the research library contain handling, reconstitution, and storage references framed strictly for in-vitro research.

Frequently asked questions